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ABSTRACT
Introduction: Decision models can be used to
conduct economic evaluations of new pharmacogenetic
and pharmacogenomic tests to ensure they offer value
for money to healthcare systems. These models require
a great deal of evidence, yet research suggests the
evidence used is diverse and of uncertain quality. By
conducting a systematic review, we aim to investigate
the test-related evidence used to inform decision
models developed for the economic evaluation of
genetic tests.
Methods and analysis: We will search electronic
databases including MEDLINE, EMBASE and NHS
EEDs to identify model-based economic evaluations
of pharmacogenetic and pharmacogenomic tests.
The search will not be limited by language or date.
Title and abstract screening will be conducted
independently by 2 reviewers, with screening of full
texts and data extraction conducted by 1 reviewer,
and checked by another. Characteristics of the
decision problem, the decision model and the test
evidence used to inform the model will be extracted.
Specifically, we will identify the reported evidence
sources for the test-related evidence used, describe
the study design and how the evidence was
identified. A checklist developed specifically for
decision analytic models will be used to critically
appraise the models described in these studies.
Variations in the test evidence used in the decision
models will be explored across the included studies,
and we will identify gaps in the evidence in terms of
both quantity and quality.
Dissemination: The findings of this work will be
disseminated via a peer-reviewed journal publication
and at national and international conferences.
INTRODUCTION
Information from genetic and genomic tests
is increasingly being used to inform patient
management decisions in healthcare
systems.1 Examples include the identiﬁcation
of individuals likely to respond to treatment
(eg, treatment with cetuximab in individuals
with K-RAS wild-type colorectal cancer2),
likely to have adverse treatment responses
(eg, HLA-B*15:02 testing to predict
Stevens-Johnson syndrome and toxic epider-
mal necrolysis when receiving carbamazo-
pine)3, or to inform treatment dose (eg,
thiopurine S-methyltransferase testing prior
to treatment with azathioprine)4. Such tests
are commonly called pharmacogenetic or
pharmacogenomic tests and are referred to
collectively as pharmacogenomic tests here-
after. Economic evaluation of these tests is
required to ensure that these interventions
are providing value for money. Test-treatment
randomised controlled trials capturing the
health outcomes arising from the actions
taken as a consequence of test results can be
complex, time-consuming, costly5 and have a
strong potential for bias,6 so are rare.7 8
Decision analytic models are therefore advo-
cated as the most systematic and transparent
method for economic evaluation.9 10
Decision analytic modelling allows the costs
and beneﬁts of strategies involving genomic
testing to inform treatment response, and
permits subsequent patient management
decisions to be compared with standard
approaches, providing insights into the trade-
offs associated with the use of these strat-
egies. However, evidence suggests that
Strengths and limitations of this study
▪ The systematic review will extensively search
decision models for evaluating pharmacogenetic
and pharmacogenomic tests.
▪ Focusing on the test-related evidence used
allows a thorough investigation into the quantity
and quality of such evidence to inform these
models.
▪ Obtaining the level of detail required to answer
the systematic review questions may be limited
by the amount of information reported in the
included articles.
Peters JL, et al. BMJ Open 2015;5:e008465. doi:10.1136/bmjopen-2015-008465 1
Open Access Protocol
group.bmj.com on November 19, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
relevant aspects of pharmacogenomic testing are not
necessarily being captured in economic evaluations,11
and there is a lack of standardisation in methods12 and
outcomes used.13 A recent methodological review14
highlighted additional issues in developing decision
models for genomic testing strategies in general, includ-
ing poor-quality effectiveness evidence and uncertainty
concerning the appropriate analytical perspective, what
resource and cost data to include, and how to measure
outcomes and effectiveness.
A key issue with model-based economic evaluations of
pharmacogenomic tests is that they generally contain
many more parameters than decision models for eco-
nomic evaluations of treatments. In addition to model-
ling the analytical and clinical validity and cost of the
genomic testing, other aspects of testing that may be
important in these evaluations include:
▸ The strength of relationship between the genetic
information and clinical outcomes: the results of
genomic tests do not themselves lead to improved
outcomes. Links need to be made between the
genomic test results, the treatment options available,
the likely treatment response and the clinical out-
comes for individuals.
▸ Estimates of the uptake of genomic testing by patients
and clinicians: even if genomic testing has greater
analytical and clinical validity than current practice, if
individuals are less likely to agree to the genomic
testing, it will have little clinical utility and may result
in fewer clinical beneﬁts compared with current
practice.
▸ Consequences of false-positive and false-negative test
results: depending on the context, the consequences
of incorrect test results may have a large impact on
the ﬁndings of the economic evaluation, for example,
severe health impacts of experiencing an adverse
drug reaction.
▸ Costs of sample collection: the costs associated with
collecting the samples required for genomic testing
should be accounted for.
▸ Costs of genetic counselling: it may be the case that
additional resources are associated with a genomic
testing strategy, so that details of the testing and the
results can be communicated to, and understood by,
those eligible for genomic testing.
▸ Test failures and/or repeated testing: it is possible
that tests may not provide usable results and add-
itional samples may need to be collected and/or tests
repeated. Accounting for the costs of obtaining addi-
tional samples and/or the time impacts of any fail-
ures and repeat testing may be important in an
economic evaluation.
Given these considerations, it is not always the case
that analytical and clinical validity drive the economic
evaluation of pharmacogenomic testing: the clinical
utility of new strategies must also be considered.5 15 It is
therefore important that the evidence base to inform
pharmacogenomic test parameters in decision models
consists of the most relevant and unbiased evidence
possible. However, research suggests that for many
model-based economic evaluations in health technology
assessment, this evidence base is often diverse and of
uncertain quality, and that sufﬁcient information is
rarely provided on how evidence has been identiﬁed.16
Although reviews of model-based economic evaluations
of pharmacogenomics tests have been conducted,11 12
they have not speciﬁcally evaluated the evidence base
informing the decision models. In this review, we will sys-
tematically investigate the use of test-related evidence in
economic evaluations of pharmacogenomic tests to
inform treatment response and subsequent patient man-
agement decisions. Test-related evidence includes evi-
dence on the analytical and clinical validity of the test,
its clinical utility including the relation between genetic
information and clinical outcomes, consequences of
incorrect test results, test failures and repeats, costs of
the test, sample collection and genetic counselling. We
will also comment on the quality and quantity of this evi-
dence. Understanding the current state of evidence
used in decision models for pharmacogenomic tests will
help identify what evidence is lacking and highlight
areas where the collection of better quality evidence
would be useful for future evaluations. This systematic
review protocol has been reported according to the
PRISMA-P reporting guidelines.17
The aim of this systematic review is to answer the fol-
lowing questions (1) What test-related evidence is being
included in model-based economic evaluations of phar-
macogenomic tests? (2) How is this evidence being iden-
tiﬁed? (3) What is the quality of this evidence? and (4)
What is the general quality of these model-based
economic evaluation?
METHODS AND ANALYSIS
Population: There will be no restrictions placed on the
populations in which pharmacogenomic testing strat-
egies are evaluated. For instance, individuals may be
newly diagnosed with a condition and yet untreated, or
may have received a number of previous treatments
before being considered for pharmacogenomic testing.
Intervention: Any pharmacogenomic test used for pre-
dicting treatment response will be included. This will
include targeted genetic tests as well as genomic tests,
and may include next-generation sequencing.
Study design: Economic evaluations of pharmacoge-
nomic tests using decision modelling will be sought
regardless of the type of modelling used. Given that
there are no restrictions on the outcomes used (see
below), this could include cost-effectiveness, cost-utility,
cost-beneﬁt, cost-minimisation and cost-consequence
analyses.
Measurement of outcomes: There will be no restrictions
on the measurement of outcomes. The systematic review
will capture all reported model outcomes, which may
include quality-adjusted life years (QALYs) from
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cost-utility analyses, cases detected from cost-
effectiveness analyses, net monetary beneﬁts from cost-
beneﬁt analyses, as well as other outcomes.
Search strategy: The search strategy will take the follow-
ing form: (terms for genetic tests) AND (a bespoke
methodological search ﬁlter to locate studies which use
decision analytic models).
The search strategy, informed by the Centre for
Reviews and Dissemination guidance18 will be run in the
following bibliographic databases:
▸ MEDLINE and MEDLINE in PROCESS (via OVID)
1946 to March 2015;
▸ EMBASE (via OVID) 1974 to March 2015 March;
▸ NHS EEDs via (The Cochrane Library, Wiley inter-
face) 1994 to March 2015;
▸ Econlit (via EBSCO Host) 1886 to March 2015; and
▸ Web of Science (via ISI) 1900 to March 2015.
As NHS EED is no longer updated, we will be search-
ing this resource as an archive. The HEED database
closed in 2015 and it is no longer possible to search it,
or access the archive. The annotated search strategy is
provided in the online supplementary material. Reports
produced by health technology assessment agencies will
also be searched to identify relevant model-based eco-
nomic evaluations that may not have been published. In
particular, the online records of the National Institute
for Health and Care Excellence in England, the
Pharmaceutical Beneﬁt Scheme in Australia and the
Canadian Agency for Drugs and Technologies in Health
will be searched.
Search limit: Where possible, the search will be limited
to human-only population groups. The search will not
be limited by language or date. Owing to the level of
information required from each article in this review,
only studies reporting full details of the decision model
will be included. Therefore, conference abstracts will be
excluded at the screening stage.
Search recording: EndNote V.7.3 (Thompson Reuters).
Study selection: There will be two stages to the screen-
ing. Following de-duplication, title and abstract screen-
ing to identify model-based economic evaluations of
pharmacogenomic tests will be completed by two
reviewers using deﬁned inclusion and exclusion criteria
(see table 1). Pilot screening of 100 hits has shown a
very high level of agreement between these two
reviewers (κ statistic of 0.93). Screening of full-text arti-
cles will be completed by one reviewer (but in discussion
with a second researcher should there be uncertainties
regarding the inclusion of an article).
Data extraction: A data extraction form will be developed
and piloted. Details to be collected will include:
▸ Characteristics of the decision problem, such as
disease/condition, gene(s), setting, perspective,
purpose of the test (eg, to predict a treatment
response, aid dose setting, predict adverse drug reac-
tions), type of test (eg, ﬂuorescence in situ hybridisa-
tion testing, Sanger sequencing, microarray testing,
whole genome sequencing).
▸ Characteristics of the decision model, such as the
model structure (eg, decision tree plus Markov
model), discount rate, time horizon, outcome mea-
sures used (eg, QALYs, cases detected), whether
probabilistic analyses were done.
▸ Which aspects of the pharmacogenomic testing strat-
egy reﬂect clinical utility/beneﬁt above current prac-
tice (eg, improved clinical validity, less invasive
testing). We will use the checklist developed by
Ferrante di Ruffano et al15 to help identify the clinical
utility of the new pharmacogenomic test(s).
▸ Characteristics of the test evidence used to inform
the model, including those stated in the introduction.
The evidence source used, its study design, how the
evidence was identiﬁed (eg, by a systematic review,
not reported), whether an assessment of the quality
of the evidence was reported to have been done. The
evidence hierarchy used by Cooper et al16 will be used
to help assess these characteristics.
▸ Whether sensitivity analyses have captured uncer-
tainty in the genomic test evidence.
▸ Whether authors have reported the use of good prac-
tice guidelines to conduct their analyses and/or
report their model and results, such as the Modelling
Good Practice Guidelines19 or the Consolidated
Health Economic Evaluations Reporting Standards
(CHEERS) statement.20
The ﬁrst 20% of included articles will have data
extracted by one reviewer and checked by another. If
there are any disagreements or inaccuracies in the data
Table 1 Inclusion and exclusion criteria
Included Excluded
Study type Model-based economic evaluations, including
cost-effectiveness analyses, cost-utility analyses,
cost-benefit analyses, cost-consequence
analyses, cost-minimisation analyses
Any non-model-based economic evaluation
Any decision model not including measurement
of costs
Population Any –
Disease/condition Any –
Purpose of testing Genetic or genomic testing to predict treatment
response
Any genomic or genetic testing used for screening,
diagnosis, prognosis or prediction of current or
future disease status
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extraction, these will be discussed. Once these disagree-
ments or inaccuracies have been addressed, one
reviewer will extract data from the remaining included
articles, in discussion with another reviewer in the case
of uncertainties.
Study quality: A modiﬁed version of the Philips et al21
checklist for the quality of economic evaluations will be
piloted before use. A copy of the checklist is given in the
appendix but may change after piloting. The Phillips
checklist is a suggested list of items for critical appraisal
of decision analytic models in health technology assess-
ment and will reﬂect a number of decision model
characteristics that will be extracted.
Data synthesis: Characteristics of the decision models
will be tabulated and summarised, drawing together simi-
larities and highlighting differences in approach and/or
quality. Variations in the test evidence used in the deci-
sion models will be explored, and we will identify gaps in
the evidence in terms of both quantity and quality.
Reporting: The systematic review will be reported in
line with the PRISMA reporting guidelines.22
Discussion: The systematic review will help to character-
ise the state of decision models evaluating pharmacoge-
nomic testing strategies. It will focus primarily on the
evidence used in the decision models to inform the
pharmacogenomic testing aspects of the evaluation;
however, it is acknowledged that the detail required may
be limited by the extent of reporting in included articles
(any evidence of this effect will also be noted).
Understanding the extent to which genetic test evidence
is incorporated into decision models, with particular
attention paid to the identiﬁcation of this evidence, its
type and quality, will highlight evidence gaps and areas
where better quality evidence is needed.
ETHICS AND DISSEMINATION
As this is secondary research, ethical approval is not
required. Disseminating this work to developers of
genetic and genomic tests will be important to highlight
current evidence gaps as future research priorities. The
ﬁndings of this work will also be very relevant to
researchers undertaking decision modelling to help con-
sider the type of test-related evidence that might be
included in future models, and also provide insight on
how to identify such evidence. Dissemination will be
undertaken via a peer-reviewed journal publication and
at national and international conferences.
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